BRAINSTORM CELL THERAPEUTICS INC

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

BCLI$1.14-7.3%Stored close · as of Jul 8, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

ANNUAL REPORT ON FORM 10-K

YEAR ENDED DECEMBER 31, 2023

TABLE OF CONTENTS

ITEM · Page
· PART I ·
1.	Business	4
1A.	Risk Factors	42
1B.	Unresolved Staff Comments	74
2.	Properties	74
3.	Legal Proceedings	75
4.	Mine Safety Disclosures	75
· PART II ·
5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	76
6.	Reserved	76
7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	76
7A.	Quantitative and Qualitative Disclosures About Market Risk	81
8.	Financial Statements and Supplementary Data	82
9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	109
9A.	Controls and Procedures	109
9B.	Other Information	110
9C.	Disclosure Regarding Foreign Jurisdictions That Prevent Inspections	110
· PART III ·
10.	Directors, Executive Officers and Corporate Governance	111
11.	Executive Compensation	117
12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	124
13.	Certain Relationships and Related Transactions, and Director Independence	126
14.	Principal Accounting Fees and Services	129
· PART IV ·
15.	Exhibits, Financial Statement Schedules	130

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents